We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma (GBM AGILE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03970447
Recruitment Status : Recruiting
First Posted : May 31, 2019
Last Update Posted : September 1, 2022
Kazia Therapeutics Limited
Kintara Therapeutics, Inc.
Biohaven Pharmaceuticals, Inc.
Vigeo Therapeutics, Inc.
Information provided by (Responsible Party):
Global Coalition for Adaptive Research

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : June 2026
Estimated Study Completion Date : June 2028